Organ-specific side effects following curative-intent radiotherapy and radical prostatectomy for non-metastatic prostate cancer: A population-based cohort study
Prognostic value of interim PSMA-PET total tumour volume for overall survival within ENZA-p, a randomised phase 2 trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901)
Progression-free survival following primary staging with [¹⁸F]PSMA-1007-PET/ceCT versus Na[¹⁸F]F-PET/ceCT in prostate cancer: Results from the PRISMA-PET randomized controlled trial
Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer
Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC
Active monitoring, surgery, and radiotherapy for cribriform-positive and cribriform-negative prostate cancer: A secondary analysis of the PROTECT randomised clinical trial
Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)